Adaptimmune

Last updated
Adaptimmune Therapeutics PLC
Company type Public
Industry
Founded2008;17 years ago (2008)
Headquarters Philadelphia, U.S.
Key people
 George Robinson
Website adaptimmune.com

Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. [1]

In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. [2] [3] [4] [5] [6] In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS). [7]

In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. [8]

References

  1. ↑ "Adaptimmune Growth Leads to Long-Term Expansion Plans in Philadelphia" (Press release). Adaptimmune. 9 October 2015. Retrieved 2024-10-15.
  2. ↑ Sunny, Miriam (5 August 2024). "US FDA approves Adaptimmune's therapy for rare type of cancer". Reuters . Retrieved 15 October 2024.
  3. ↑ McCook, Allison (8 October 2024). "A Navy Yard biotech designed a first-of-its-kind therapy for rare cancer. Now, it waits for patients". The Philadelphia Inquirer . Retrieved 15 October 2024.
  4. ↑ Brzyski, Laura (22 June 2021). "The Navy Yard-Based Biopharma Company Engineering T-Cell Receptors to Destroy Cancerous Solid Tumors". Philadelphia . Retrieved 15 October 2024.
  5. ↑ Ward, Andrew (4 February 2016). "Hedge fund pioneer is force behind hotly tipped biotech companies". Financial Times . Retrieved 15 October 2024.
  6. ↑ Harrison, Charlotte (2 October 2024). "TCR cell therapies vanquish solid tumors — finally" . Nature . doi:10.1038/s41587-024-02435-5 . Retrieved 15 October 2024.
  7. ↑ "Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)". Adaptimmune. 2025-01-13. Retrieved 2025-10-18.
  8. ↑ "Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds". Adaptimmune. 2025-07-28. Retrieved 2025-10-18.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.